Babu S, Sandiford NA, Vrahas M. Use of Teriparatide to improve fracture healing: What is the evidence? World J Orthop 2015; 6(6): 457-461 [PMID: 26191492 DOI: 10.5312/wjo.v6.i6.457]
Corresponding Author of This Article
Nemandra A Sandiford, FRCS (Trauma and Orthopaedics), Lower Limb and Tumor Reconstruction Fellow, University of British Columbia, 2329 West Mall, Vancouver V5Z 1M9, British Columbia, Canada. nemsandiford@hotmail.com
Research Domain of This Article
Orthopedics
Article-Type of This Article
Minireviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Orthop. Jul 18, 2015; 6(6): 457-461 Published online Jul 18, 2015. doi: 10.5312/wjo.v6.i6.457
Use of Teriparatide to improve fracture healing: What is the evidence?
Satish Babu, Nemandra A Sandiford, Mark Vrahas
Satish Babu, Core Surgical Trainee, St. George’s Hospital, London SW17 0QT, United Kingdom
Nemandra A Sandiford, Lower Limb and Tumor Reconstruction Fellow, University of British Columbia, Vancouver V5Z 1M9, British Columbia, Canada
Mark Vrahas, Orthopaedic Trauma Service, Massachusetts General Hospital, Boston, MA 02114, United States
Author contributions: All authors contributed to this manuscript.
Conflict-of-interest statement: We, the authors of this scientific paper, do hereby state that we have no conflicts of interest to declare.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Nemandra A Sandiford, FRCS (Trauma and Orthopaedics), Lower Limb and Tumor Reconstruction Fellow, University of British Columbia, 2329 West Mall, Vancouver V5Z 1M9, British Columbia, Canada. nemsandiford@hotmail.com
Telephone: +1-208-3069032
Received: February 12, 2015 Peer-review started: February 12, 2015 First decision: April 10, 2015 Revised: May 2, 2015 Accepted: June 1, 2015 Article in press: June 2, 2015 Published online: July 18, 2015 Processing time: 152 Days and 8.9 Hours
Core Tip
Core tip: Teriparatide contains the biologically active component of Parathyroid Hormone. It is utilised in osteoporosis for its ability to increase bone mass and prevent fractures. Research suggests Teriparatide may improve callus volume, callus mineralisation, bone mineral content and successful union. However most research come from animal models. Human research, whilst supporting Teriparatide use, mostly comprises low level evidence such as case series. Currently many United States physicians use Teriparatide “off license” for fractures and non-unions. We suggest more, well designed, human randomised controlled trials are required before Teriparatide can become a mainstream option in the conservative management of fractures and non-unions.
